Added to YB: 2026-10-06
Pitch date: 2026-09-28
NAUT [bullish]
Nautilus Biotechnology, Inc.
+81.51%
current return
Author Info
No bio for this author
Company Info
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Market Cap
$238.0M
Pitch Price
$1.19
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.54
P/E
-4.19
EV/Sales
956.59
Sector
Life Sciences Tools and Services
Category
growth
Nautilus: Tesla for Proteomics.
NAUT (hold): Nautilus, valued just above $120M after a roughly 70% decline since March, is building the only platform able to read the proteome at proteoform resolution. Its assay-development cycle has compressed from five years for tau to about one year for oncology, with roughly 20 assays targeted by mid-2028. The position remains micro-sized because revenue is immaterial, cash is thin and a raise is expected before mid-2027; further investment depends on execution milestones and financing terms.
Read full article (3 min)